Infigratinib demonstrated efficacy in previously treated, unresectable locally advanced, or metastatic CCA with FGFR2 fusion or rearrangement in the CBGJ398X2204 trial (NCT02150967, phase II). Here, FGFR2 is linked to cholangiocarcinoma.